SCHEMBL5408247

SCHEMBL5408247

COc1cc2nc(N)c(Oc3ccccc3)cc2cc1C(N)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.64
ALDH1A1 P00352 3/20 0.64
HPGD P15428 3/20 0.64
GLA P06280 1/20 0.64
GAA P10253 1/20 0.64
LMNA P02545 1/20 0.56
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PLA2G10 O15496 1/20 0.48
CTNNB1 P35222 1/20 0.47
KDR P35968 3/20 0.46
AURKA O14965 2/20 0.46
MET P08581 2/20 0.46
TEK Q02763 2/20 0.46
AURKB Q96GD4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408253 0.84 KDM4E (0.52) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL22499897 0.79 KDM4E (0.44) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL8352155 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL8584230 0.78 ALDH1A1 (0.71) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL31218163 0.76 KDR (0.71) KDRAURKAMETTEKAURKB
SCHEMBL11546744 0.75 HPGD (0.70) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL27159618 0.74 ALDH1A1 (0.41) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL26129231 0.72 ALDH1A1 (0.49) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL22499901 0.72 KDR (0.53) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL32667941 0.72 KDM4E (0.66) KDM4EALDH1A1MAPTPLA2G10CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021150792-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS MICURX PHARMACEUTICALS, INC. (US) 2021-07-29 WO disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R KDM4E 2371/4885ALDH1A1 1164/4885HPGD 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.